Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manuela Schmidinger

Showing results (81-90 of 112) with videos related to

Pageof 12
Sort By:
European Urology Oncology|March 24, 2021
First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysisFahad Quhal, Keiichiro Mori, Andreas Bruchbacher, et al.
Cancer Treatment Reviews|June 21, 2021
Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysisKeiichiro Mori, Benjamin Pradere, Fahad Quhal, et al.
The Oncologist|March 15, 2019
Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study)Manuela Schmidinger, Aristotelis Bamias, Giuseppe Procopio, et al.
Oncotarget|October 15, 2016
MiR-99b-5p expression and response to tyrosine kinase inhibitor treatment in clear cell renal cell carcinoma patientsMagdalena Lukamowicz-Rajska, Christiane Mittmann, Michael Prummer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2022
Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 TrialBrian I Rini, Javid J Moslehi, Marc Bonaca, et al.
Immunotherapy|September 11, 2023
Association between age and efficacy of first-line immunotherapy-based combination therapies for mRCC: a meta-analysisTakafumi Yanagisawa, Fahad Quhal, Tatsushi Kawada, et al.
European Urology Oncology|January 7, 2022
Pembrolizumab outperforms tyrosine kinase inhibitors as adjuvant treatment in patients with high-risk renal cell carcinoma after nephrectomyEkaterina Laukhtina, Fahad Quhal, Keiichiro Mori, et al.
The Oncologist|August 5, 2015
Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma--Analysis Using Diagnostic NodesChristian Rothermundt, Alexandra Bailey, Linda Cerbone, et al.
BJU International|April 25, 2024
First-line immunotherapy of metastatic renal cell carcinoma: an updated network meta-analysis including triplet therapyTakafumi Yanagisawa, Tatsushi Kawada, Kensuke Bekku, et al.
ESMO Open|July 17, 2020
Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinomaStefanie Aeppli, Eric Innocents Eboulet, Tim Eisen, et al.
Pageof 12

Showing results (81-90 of 112) with videos related to

Sort By:
Pageof 12
European Urology Oncology|March 24, 2021
First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysisFahad Quhal, Keiichiro Mori, Andreas Bruchbacher, et al.
Cancer Treatment Reviews|June 21, 2021
Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysisKeiichiro Mori, Benjamin Pradere, Fahad Quhal, et al.
The Oncologist|March 15, 2019
Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study)Manuela Schmidinger, Aristotelis Bamias, Giuseppe Procopio, et al.
Oncotarget|October 15, 2016
MiR-99b-5p expression and response to tyrosine kinase inhibitor treatment in clear cell renal cell carcinoma patientsMagdalena Lukamowicz-Rajska, Christiane Mittmann, Michael Prummer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2022
Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 TrialBrian I Rini, Javid J Moslehi, Marc Bonaca, et al.
Immunotherapy|September 11, 2023
Association between age and efficacy of first-line immunotherapy-based combination therapies for mRCC: a meta-analysisTakafumi Yanagisawa, Fahad Quhal, Tatsushi Kawada, et al.
European Urology Oncology|January 7, 2022
Pembrolizumab outperforms tyrosine kinase inhibitors as adjuvant treatment in patients with high-risk renal cell carcinoma after nephrectomyEkaterina Laukhtina, Fahad Quhal, Keiichiro Mori, et al.
The Oncologist|August 5, 2015
Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma--Analysis Using Diagnostic NodesChristian Rothermundt, Alexandra Bailey, Linda Cerbone, et al.
BJU International|April 25, 2024
First-line immunotherapy of metastatic renal cell carcinoma: an updated network meta-analysis including triplet therapyTakafumi Yanagisawa, Tatsushi Kawada, Kensuke Bekku, et al.
ESMO Open|July 17, 2020
Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinomaStefanie Aeppli, Eric Innocents Eboulet, Tim Eisen, et al.
Pageof 12